Glucagon, Glucagon-like Peptide (e.g., Glp-1, Glp-2, Etc.) Or Derivative Patents (Class 514/11.7)
-
Patent number: 8975227Abstract: The present invention provides a composition (e.g., a pharmaceutical composition) comprising at least one delivery agent compound and glucagon. Preferably, the composition includes a therapeutically effective amount of glucagon and the delivery agent compound. The composition of the present invention facilitates the delivery of glucagon and increases its bioavailability compared to administration without the delivery agent compound.Type: GrantFiled: July 17, 2006Date of Patent: March 10, 2015Assignee: Emisphere Technologies, Inc.Inventors: Nai Fang Wang, Puchun Liu, Steven Dinh, Michael M. Goldberg, Ehud Arbit
-
Publication number: 20150065422Abstract: Disclosed are drug delivery systems for the delivery of small molecule and macromolecular drugs. More particularly, disclosed are substituted analogs of 3,6-di(alkyl-4 aminobutyl)-2,5-diketopiperazine (which may also be referred to DKP), their use in the formulation of both small molecule and macromolecular drugs including therapeutic, prophylactic and diagnostic agents, stabilizing agents and systems for their delivery.Type: ApplicationFiled: November 7, 2014Publication date: March 5, 2015Inventor: Kelly Sullivan Kraft
-
Patent number: 8969288Abstract: Prodrug formulations of glucagon superfamily peptides are provided wherein the glucagon superfamily peptide has been modified by the linkage of a dipeptide to the glucagon superfamily through an amide bond linkage. The prodrugs disclosed herein have extended half lives and are converted to the active form at physiological conditions through a non-enzymatic reaction driven by chemical instability.Type: GrantFiled: December 18, 2009Date of Patent: March 3, 2015Assignee: Indiana University Research and Technology CorporationInventors: Richard D. DiMarchi, Binbin Kou
-
Patent number: 8968716Abstract: Disclosed herein are an in situ-forming, bioadhesive hydrogel and the medical uses thereof. Being formed by in situ crosslinking through an enzymatic reaction, the hydrogel has an advantage over conventional bioadhesive hydrogels in terms of biocompatibility. In addition, the in situ-forming bioadhesive hydrogel has excellent biocompatibility and mechanical strength and has excellent tissue adhesiveness thanks to modification with/without dopa derivatives. The hydrogel finds a variety of applications in the biomedical field, including bioadhesives or hemostats, implant substances for tissue regeneration and augmentation, carriers for delivering biologically active materials or drugs, etc.Type: GrantFiled: September 2, 2010Date of Patent: March 3, 2015Assignee: Ajou University Industry-Academic Cooperation FoundationInventors: Ki-Dong Park, Yoon-Ki Joung, Kyung-Min Park, Eu-Gene Lih
-
Publication number: 20150057227Abstract: The use of GLP-1 receptor agonists, such as glucagon-like peptide-1 (GLP-1) or exenatide, for the treatment of cancer is described. The GLP-1 receptor agonists are typically delivered using an implanted osmotic delivery device that provides for continuous delivery of the GLP-1 receptor agonist for at least one month. Additional beneficial agents, such as anticancer agents, can also be administered.Type: ApplicationFiled: October 27, 2014Publication date: February 26, 2015Inventor: Karling Alice Leung
-
Publication number: 20150056167Abstract: Human proIslet Peptides (HIP) and HIP analogs and derivatives thereof, derived from or homologous in sequence to the human REG3A protein, chromosome 2p12, are able to induce islet neogenesis from endogenous pancreatic progenitor cells. Human proIslet Peptides are used either alone or in combination with other pharmaceuticals in the treatment of type 1 and type 2 diabetes and other pathologies related to aberrant glucose, carbohydrate, andor lipid metabolism, insulin resistance, overweight, obesity, polycystic ovarian syndrome, eating disorders and the metabolic syndrome.Type: ApplicationFiled: September 4, 2014Publication date: February 26, 2015Inventors: Claresa S. Levetan, Loraine V. Upham
-
Publication number: 20150057220Abstract: Fused aromatic phosphonates of structural formula I are precursors to inhibitors of protein tyrosine phosphatase-1B (PTP-1B). The compounds of the present invention are therefore useful for the treatment in a mammal of a disorder, condition, or disease responsive to inhibition of protein tyrosine phosphatase-1B, including Type 2 diabetes, insulin resistance, a lipid disorder, obesity, Metabolic Syndrome, and cancer.Type: ApplicationFiled: April 16, 2013Publication date: February 26, 2015Inventors: Michel Therien, Yves Leblanc, Yongxin Han
-
Publication number: 20150056160Abstract: An invention relating to therapeutic pharmacological agents and methods to chemically induce intracellular hyperthermia and/or free radicals for the diagnosis and treatment of infections, malignancy and other medical conditions. The invention relates to a process and composition for the diagnosis or killing of cancer cells and inactivation of susceptible bacterial, parasitic, fungal, and viral pathogens by chemically generating heat, and/or free radicals and/or hyperthermia—inducible immunogenic determinants by using mitochondrial uncoupling agents, especially 2,4 dinitrophenol and, their conjugates, either alone or in combination with other drugs, hormones, cytokines and radiation.Type: ApplicationFiled: February 24, 2014Publication date: February 26, 2015Inventors: Nicholas Bachynsky, Woodie Roy
-
Publication number: 20150057605Abstract: There is provided glucagon formulations suitable for preparing coatings on microneedle patches for the transdermal delivery of glucagon. The coated patches may be used for the treatment of low blood sugar in diabetic patients. Also provided are glucagon loaded patches, methods for their preparation, and methods of their use.Type: ApplicationFiled: August 22, 2014Publication date: February 26, 2015Inventors: Mahmoud Ameri, Peter E. Daddona, Yi Ao
-
Publication number: 20150056285Abstract: The disclosure provides one-component, injectable, sustained release formulations which comprise microspheres containing active pharmaceutical ingredients (e.g., exenatide), wherein the microspheres are suspended in a non-aqueous carrier. The non-aqueous carrier can be an oil, a fractionated oil, triglycerides, diglycerides, monoglycerides, propylene glycol fatty acid diesters, and the like. The formulations offer distinct advantages of long shelf life for the stability and potency of the formulation and sustained release of active pharmaceutical ingredients to reduce the frequency of medication dosing and to increase patient compliance.Type: ApplicationFiled: October 27, 2014Publication date: February 26, 2015Inventors: Mary L. HOUCHIN, Robin H. LEE, Hong QI, Greg OEHRTMAN, Robert N. JENNINGS, Scott H. COLEMAN
-
Publication number: 20150057221Abstract: The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof comprising a drug linker conjugate D-L, wherein -D is an amine containing biologically active moiety; and -L is a non-biologically active linker moiety -L1 represented by formula (I): wherein the dashed line indicates the attachment to the amine of the biologically active moiety and wherein R1, R1a, R2, R2a, R3, R3a, X, X1, X2, X3 have the meaning as indicated in the description and the claims and wherein L1 is substituted with one to four groups L2-Z and optionally further substituted, provided that the hydrogen marked with the asterisk in formula (I) is not replaced by a substituent; wherein L2 is a single chemical bond or a spacer; and Z is a carrier group. The invention also relates to A-L, wherein A is a leaving group, pharmaceutical composition comprising said prodrugs and their use as medicaments.Type: ApplicationFiled: October 30, 2014Publication date: February 26, 2015Inventors: Felix Cleemann, Ulrich Hersel, Silvia Kaden, Harald Rau, Thomas Wegge
-
Publication number: 20150051141Abstract: This invention relates to novel compositions comprising analogs of glucagon, wherein the analog comprises an ?-amino acid and at least one ?-amino acid. Administration of the compositions may be used for effecting treatment or prevention of a plurality of disease states caused by dysfunctional biochemical or biological pathways, including diabetes and other metabolic disorders. The compositions and methods of this invention are particularly useful to identify novel therapeutic modulators of in-vivo receptor activity with extended half-lives and relevant bioactivity as compared to the naturally translated polypeptides upon which the analogs are derived.Type: ApplicationFiled: April 5, 2012Publication date: February 19, 2015Applicant: Longevity Biotech, Inc.Inventors: Scott Shandler, Samuel H. Gellman
-
Publication number: 20150045295Abstract: A breath-powered, dry powder inhaler, a cartridge, and a pulmonary drug delivery system are provided. The dry powder inhaler can be provided with or without a unit dose cartridge for using with the inhaler. The inhaler and/or cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, peptides and proteins such as insulin and glucagon-like peptide 1 for the treatment of diabetes and/or obesity. The dry powder inhaler is compact; can be provided in various shapes and sizes, colors, and comprises a housing, a mouthpiece, a cartridge placement area, and a mechanism for opening and closing the medicament cartridge. The device is easy to manufacture, provides a pre-metered single unit dose, it is relatively easy to use, and can be reusable or disposable.Type: ApplicationFiled: October 21, 2014Publication date: February 12, 2015Inventors: Chad C. Smutney, P. Spencer Kinsey, Carl R. Sahi, Benoit Adamo, John M. Polidoro, Scott McLean, Dennis Overfield, Kelly S. Kraft, Karla Somerville
-
Patent number: 8951959Abstract: Provided is a glucagon-like peptide-1 (GLP-1) analog shown as the following formula, wherein X is selected from glycine and glycinamide. The GLP-1 analog has a non-proteogenic amino acid residue in position 8 relative to the sequence GLP-1, and is acylated with a moiety comprising two acidic groups to the lysine residue in position 26. The GLP-1 analog is resistant to dipeptidyl peptidase IV so as to have an extended half-life in vivo. Also provided is a use of the GLP-1 analog in conquering blood sugar.Type: GrantFiled: April 29, 2011Date of Patent: February 10, 2015Assignee: Betta Pharmaceuticals Co., Ltd.Inventors: Yinxiang Wang, Fenlai Tan, Shaojing Hu, Xiangdong Zhao, Cunbo Ma, Yanping Wang, Xiaoyan Shen, Lieming Ding, Yunyan Hu, Hong Cao, Wei Long
-
Publication number: 20150037359Abstract: The present invention relates to extended recombinant polypeptide (XTEN) compositions, conjugate compositions comprising XTEN and XTEN linked to cross-linkers useful for conjugation to pharmacologically active payloads, methods of making highly purified XTEN, methods of making XTEN-linker and XTEN-payload conjugates, and methods of using the XTEN-cross-linker and XTEN-payload compositions.Type: ApplicationFiled: February 27, 2013Publication date: February 5, 2015Applicant: AMUNIX OPERATING, INC.Inventors: Volker Schellenberger, Vladimir Podust, Chia-Wei Wang, Bryant McLaughlin, Bee-Cheng Sim, Sheng Ding, Chen Gu
-
Publication number: 20150038416Abstract: The invention relates to compounds that modulate the glucagon-like peptide 1 (GLP-1) receptor, methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds are act as modulators or potentiators of GLP-1 receptor on their own, or with receptor ligands including GLP-1 peptides GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where “” represents either or both the R and S form of the compound): where A, B, C, Y1, Y2, Z, R1, R2, R3, R4, R5, W1, n, p and q are as defined herein.Type: ApplicationFiled: June 5, 2014Publication date: February 5, 2015Inventors: Marcus F. Boehm, Esther Martinborough, Manisha Moorjani, Junko Tamiya, Liming Huang, Adam R. Yeager, Enugurthi Brahmachary, Thomas Fowler, Andrew Novak, Premji Meghani, Michael Knaggs
-
Publication number: 20150038417Abstract: A method for the prevention or treatment of alcoholism and drug addiction comprising administering to a subject in need thereof a therapeutically effective amount of a GLP-1 agonist.Type: ApplicationFiled: December 10, 2012Publication date: February 5, 2015Inventor: Kirsten Raun
-
Publication number: 20150025003Abstract: The invention relates to protracted Glucagon-Like Peptide-1 (GLP-1) derivatives and therapeutic uses thereof. The GLP-1 derivative of the invention comprises a modified GLP-1(7-37) sequence having a total of 2-12 amino acid modifications, including Glu22 and Arg26, and being derivatised with an albumin binding residue or pegylated in position 18, 20, 23, 30, 31, 34, 36, 37, or 39. These compounds are useful in the treatment or prevention of diabetes type 2 and related diseases. The compounds are potent, stable, have long half-lives, a high affinity of binding to albumin, and/or a high affinity of binding to the extracellular domain of the GLP-1 receptor (GLP-1R), all of which is of potential relevance for the overall aim of achieving long-acting, stable and active GLP-1 derivatives with a potential for once weekly administration.Type: ApplicationFiled: October 3, 2014Publication date: January 22, 2015Inventors: Jane Spetzler, Lauge Schaeffer, Jesper Lau, Thomas Kruse, Patrick W. Garibay, Steffen Reedtz-Runge, Henning Thoegersen, Ingrid Pettersson
-
Publication number: 20150025006Abstract: One aspect of the present invention is a pharmaceutical combination comprising (a) an anti-inflammatory agent/anti-oxidant agent conjugate; and (b) an insulin secretogogue, an insulin sensitizer, an alpha-glucosidase inhibitor, a peptide analog, or a combination thereof. Another aspect of the invention relates to methods of treating metabolic disorders with such conjugates.Type: ApplicationFiled: September 14, 2012Publication date: January 22, 2015Applicant: Genmedica Therapeutics SLInventors: Julio Cesar Castro Palomino Laria, Luc Marti Clauzel, Antonio Zorzano Olarte, Silvia Garcia Vicente, Alec Mian
-
Patent number: 8933039Abstract: Analogs of glucagon-like peptide 2, a product of glucagon gene expression, have been identified as intestinal tissue growth factors. Their formulation as pharmaceutical, and therapeutic use in treating disorders of the small bowel, are described.Type: GrantFiled: June 15, 2010Date of Patent: January 13, 2015Assignees: NPS Pharmaceuticals, Inc., 1149336 Ontario Inc.Inventors: Daniel J Drucker, Anna E. Crivici, Martin Sumner-Smith
-
Publication number: 20150011462Abstract: The invention relates to derivatives of GLP-1 like peptides which are C-terminally extended analogues of native GLP-1. The derivatives comprise two side chains, one at a position corresponding to position 42, and one at a position corresponding to position 18, 23, 27, 31, 36, or 38, wherein both positions are when compared to GLP-1(7-37). The side chains comprise a C19, C20, or C22 diacid protracting moiety and optionally a linker. The invention also relates to intermediate products in the form of novel GLP-1 analogues incorporated in the derivatives of the invention, as well as pharmaceutical compositions and medical uses of the derivatives. The derivatives have very long half-lives while maintaining a satisfactory potency, which makes them potentially suitable for once-monthly administration.Type: ApplicationFiled: July 2, 2014Publication date: January 8, 2015Inventors: Steffen Reedtz-Runge, Jacob Kofoed, Christian Wenzel Tornoee, Per Sauerberg
-
Publication number: 20150010508Abstract: The present invention provides methods and kits for treating diseases and conditions associated with impaired pancreatic function. The present invention further provides methods of stimulating islet cell neogenesis and stimulating islet cell differentiation from progenitor cells.Type: ApplicationFiled: July 21, 2014Publication date: January 8, 2015Inventors: Claresa S. Levetan, Loraine V. Upham
-
Publication number: 20150005233Abstract: This invention provides compounds, compositions, and methods for treating hypogly.Type: ApplicationFiled: February 8, 2013Publication date: January 1, 2015Applicant: Seneb Biosciences, Inc.Inventor: Shawn DeFrees
-
Publication number: 20150005232Abstract: Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, and R6 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating obesity and related diseases, disorders, and conditions associated with MetAP2.Type: ApplicationFiled: February 28, 2013Publication date: January 1, 2015Applicant: Takeda Pharmaceutical Company LimitedInventors: Zacharia Cheruvallath, Philip Erickson, Jun Feng, Mallareddy Komandla, John David Lawson, Christopher McBride, Joanne Miura, Sean Murphy, Mingnam Tang, Huong-Thu Ton-Nu
-
Publication number: 20150005230Abstract: Provided are methods relating to the use of CDP-therapeutic agent conjugates for the treatment of a disease or disorder, e.g., autoimmune disease, inflammatory disease, central nervous system disorder, cardiovascular disease, or metabolic disorder. Also provided are CDP-therapeutic agent conjugates, particles comprising CDP-therapeutic agent conjugates, and compositions comprising CDP-therapeutic agent conjugates.Type: ApplicationFiled: January 30, 2014Publication date: January 1, 2015Applicant: CERULEAN PHARMA INC.Inventor: Scott Eliasof
-
Publication number: 20140377344Abstract: Provided herein are methods and compositions for oral administration of therapeutic proteins, improved protease inhibitor preparations, methods for producing same, and compositions comprising same.Type: ApplicationFiled: January 31, 2013Publication date: December 25, 2014Inventor: Avraham Hershko
-
Publication number: 20140378381Abstract: The present invention provides an oil-in-water nanoemulsion containing glucagon, an oily phase, and an aqueous phase, wherein the glucagon is physically and chemically stable and the nanoemulsion is suitable for administration by manual injection or by a pump to treat hypoglycemia.Type: ApplicationFiled: June 25, 2014Publication date: December 25, 2014Inventors: Andrew Xian Chen, Norman Keith Orida, Hailiang Chen, Hau Huu Dang
-
Publication number: 20140371148Abstract: Peptide-peptidase inhibitor conjugate molecules are disclosed. These conjugate molecules are useful as agents for the treatment and prevention of metabolic and cardiovascular diseases, disorders, and conditions. Such diseases, conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, and other diabetes-related disorders.Type: ApplicationFiled: June 18, 2014Publication date: December 18, 2014Inventors: Soumitra S. GHOSH, Josue ALFARO-LOPEZ, Lawrence J. D'Souza, Odile Esther LEVY, Qing LIN, Christopher J. SOARES
-
Publication number: 20140363492Abstract: The delivery of biopharmaceutical and other therapeutic agents parenterally to an animal via a minimally invasive, low pain administration is provided. The agents are delivered to the patient via, e.g., the epidermal, dermal, or subcutaneous layer of the skin in a concentrated fours of injectable paste of slurry.Type: ApplicationFiled: May 28, 2014Publication date: December 11, 2014Applicant: XERIS PHARMACEUTICALS, INC.Inventors: Steven PRESTRELSKI, Kevin BRODBECK
-
Publication number: 20140357552Abstract: The present invention provides a novel peptide compound having an activating action on GLP-1 receptors and GIP receptors and use of the peptide compound as a medicament. Specifically, a peptide containing a partial sequence represented by the formula (I) or a salt thereof and a medicament comprising the same are provided. (I) P1-Tyr-Aib-Glu-Gly-Thr-?MePhe-Thr-Ser-Asp-Tyr- A11-A12-A13-Leu-Asp-A16-A17-Ala-Gln-A20-Glu- Phe-Val-Lys-Trp-Leu-Leu-Lys-A29 wherein each symbol is as defined herein.Type: ApplicationFiled: May 27, 2014Publication date: December 4, 2014Applicant: Takeda Pharmaceutical Company LimitedInventors: Taiji ASAMI, Ayumu NIIDA
-
Publication number: 20140349928Abstract: Described herein are methods of syntheses and therapeutic uses of covalently modified peptides and/or proteins. The covalently modified peptides and/or proteins allow for improved pharmaceutical properties of peptide and protein-based therapeutics.Type: ApplicationFiled: May 17, 2012Publication date: November 27, 2014Applicant: Mederis Diabetes, LLCInventor: John J. Nestor
-
Publication number: 20140349922Abstract: Pegylated and reverse pegylated GLP-1/Glucaron receptor agonists including pharmaceutical compositions comprising the same and methods of using the same are disclosed.Type: ApplicationFiled: June 4, 2012Publication date: November 27, 2014Inventors: Udi Eyal Fima, Oren Hershkóvitz
-
Patent number: 8895498Abstract: The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.Type: GrantFiled: August 22, 2012Date of Patent: November 25, 2014Assignees: AstraZeneca Pharmaceuticals, LP, Amylin Pharmaceuticals, LLCInventors: Odile Esther Levy, Alain D. Baron, Lawrence J. D'Souza, Mary Erickson, Soumitra G. Ghosh, Michael R. Hanley, Samuel Janssen, Carolyn M. Jodka, Diana Y. Lewis, Christine M. Mack, David G. Parkes, Richard A. Pittner, Christopher J. Soares, Ved Srivastava, Andrew A. Young, Thao Le
-
Publication number: 20140341891Abstract: The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient, for example, LYXUMIA (lixisenatide), LEMTRADA (alemtuzumab), REGN727/SAR236553 (alirocumab), SAR2405550/BSI-201 (iniparib), OTAMIXABAN (otamixaban), SARILUMAB (sarilumab), LANTUS and LYXUMIA (insulin glargine and lixisenatide) or VISAMERIN/MULSEVO (semuloparin sodium).Type: ApplicationFiled: April 23, 2014Publication date: November 20, 2014Applicant: CORNING INCORPORATEDInventors: Wendell P. Weeks, Robert Anthony Schaut, Steven Edward DeMartino, John Stephen Peanasky
-
Patent number: 8889622Abstract: The present invention relates to methods of inhibiting seizure in a subject. In particular, the invention provides methods of increasing brain leptin levels in a subject.Type: GrantFiled: July 25, 2008Date of Patent: November 18, 2014Assignee: Washington UniversityInventors: Kwee Liu Lin Thio, Kelvin A. Yamada
-
Publication number: 20140336107Abstract: The present invention relates, inter alia, to certain peptide conjugates, and to the use of the conjugates in the treatment of a variety of diseases or disorders, including diabetes (type 1 and/or type 2) and diabetes-related diseases or disorders.Type: ApplicationFiled: November 2, 2012Publication date: November 13, 2014Inventors: Jakob Lind Tolborg, Trine Neerup, Keid Fosgerau, Torben Østerlund, Dorthe Lennert Christensen Almholt, Lone Frost Larsen
-
Publication number: 20140336118Abstract: A peptide of the formula R1-NH-HAEGTFTSDVSSYLEGQAAKEFIAWLVK-CONR2R3 wherein R=H or an organic compound comprising from 1 to 10 carbon atoms and R2 R3=independently H or an alkyl group of 1 to 4 carbon atoms; or certain analogues of said GLP-1 peptide can be used for the treatment and prophylaxis of heart ischemia-reperfusion injuryType: ApplicationFiled: October 29, 2012Publication date: November 13, 2014Inventors: Marek Treiman, Henrik K. Salling, Klaus Döhler, Thomas Engstrøm
-
Patent number: 8883728Abstract: Pharmaceutical compositions and methods for delivering a polypeptide to the central nervous system of a mammal via intranasal administration are provided. The polypeptide can be a catalytically active protein or an antibody, antibody fragment or antibody fragment fusion protein. The polypeptides are formulated with one or more specific agents.Type: GrantFiled: November 24, 2010Date of Patent: November 11, 2014Assignee: Aegis Therapeutics, LLCInventor: Edward T. Maggio
-
Publication number: 20140329742Abstract: The present invention relates to novel analogs of PYY that have an improved therapeutic profile when compared to native human PYY. These novel PYY analogs are useful in the treatment of obesity, diabetes, and other disorders.Type: ApplicationFiled: April 30, 2014Publication date: November 6, 2014Applicant: GlaxoSmithKline Intellectual Property (No. 2) LimitedInventors: Steven Thomas Dock, Andrew James Carpenter, Robert Neil Hunter, III, Yulin Wu, Ved P. Srivastava
-
Publication number: 20140328794Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating or preventing diseases, disorders or conditions related to diabetes mellitus using albumin fusion proteins of the invention.Type: ApplicationFiled: July 18, 2013Publication date: November 6, 2014Applicant: Human Genome Sciences, Inc.Inventors: Craig A. Rosen, William A. Haseltine, Steven M. Ruben
-
Patent number: 8871713Abstract: Stabilized solid and liquid pharmaceutical formulations comprising a GRF molecule as active ingredient, such as GRF analogs including those comprising an N-terminal-attached hydrophobic moiety, such as [trans-3-hexenoyl]hGHRH (1-44) amide, are disclosed. The formulation comprises a GRF molecule or a pharmaceutically acceptable salt thereof and a ?-cyclodextrin which is not conjugated to the GRF molecule or salt thereof. Also disclosed is the use of the formulation for the treatment of various conditions, methods of preparing the formulation, as well as kits containing it. Methods of stabilizing (e.g., with respect to chemical stability) such GRF molecules, as well as methods of inhibiting their deamidation at Asn8, are also disclosed.Type: GrantFiled: March 14, 2013Date of Patent: October 28, 2014Assignee: Theratechnologies Inc.Inventors: Kirill I Shingel, Daniel Fleury
-
Publication number: 20140316333Abstract: A dissolving solid solution perforator (SSP) patch for oral cavity administration may include at least one perforator. The at least one perforator may contain a first drug and be configured to pierce an outside layer of an oral cavity for promptly delivering the first drug. The at least one perforator may penetrate an epithelium layer of the oral cavity and to deliver the antimigraine drug into blood vessels in a submucosa layer.Type: ApplicationFiled: October 29, 2012Publication date: October 23, 2014Inventor: Sung-Yun KWON
-
Publication number: 20140314853Abstract: A new microsphere formulation (composition) for controlled- or sustained-release delivery of therapeutic ingredient(s), mainly peptides and proteins not over 10K in molecular weight, comprises at least a therapeutic ingredient, a helping agent (such as PH sensitive agent whose solubility is a function of pH) and a biodegradable polymer. The therapeutic ingredient(s) and the helping agent are in the form of fine particles, less than 1O um in diameter, encapsulated in the polymer which forms the microsphere matrix. A method for preparing the composition comprises a step of in-situ precipitating the therapeutic ingredient(s) and the helping agent to the fine particles and successive steps for forming the microspheres. Such a microsphere formulation offers a well-controlled release profile for prolonged period and encapsulation efficiency over 95%.Type: ApplicationFiled: December 5, 2012Publication date: October 23, 2014Inventors: Tuo Jin, Zhenhua Hu, Weien Yuan
-
Publication number: 20140309169Abstract: Disclosed are compositions and methods for inhibiting preventing, reducing delayed graft function, allograft rejection or ischemia reperfusion injury.Type: ApplicationFiled: February 8, 2012Publication date: October 16, 2014Inventor: Richard P. Shannon
-
Publication number: 20140309168Abstract: Provided are compounds and methods of making compounds containing two or three groups derived from a peptide, such as enfuvirtide or exenatide, covalently bound to a linker. The compounds may contain polyethylene glycol groups to enhance solubility and pharmacokinetic properties. The compounds are useful for the treatment of diseases or conditions subject to treatment with the parent peptide, such as HIV and AIDS in the case of enfuvirtide, or diabetes in the case of exenatide.Type: ApplicationFiled: March 19, 2014Publication date: October 16, 2014Applicant: AmideBio, LLCInventor: Mary S. Rosendahl
-
Publication number: 20140303083Abstract: The invention relates to a derivative of a GLP-1 peptide, which peptide has two Lys residues, namely a first and a second Lys residue, and a maximum of eight amino acid changes as compared to GLP-1(7-37) (SEQ ID NO: 3), which derivative comprises two protracting moieties attached to the epsilon amino group of said first and second Lys residue, respectively, via a linker, wherein the protracting moiety is selected from Chem. 15: HOOC—(CH2)x-CO—*, and Chem. 16: HOOC—C6H4-O—(CH2)y-CO—*, in which x is an integer in the range of 10-16, and y is an integer in the range of 8-12; and the linker comprises a first linker element *—NH—CH(CH2OH)—CO—*. A preferred linker is g Glu-Ser-Ser-Gly-Ser-Ser-Gly (SEQ ID NO: 2). The derivative of the invention has a very good potency, and a very good binding to the GLP-1 receptor. The invention also relates to the pharmaceutical use of the derivative, for example in the treatment and/or prevention of all forms of diabetes and related diseases.Type: ApplicationFiled: September 6, 2012Publication date: October 9, 2014Applicant: NOVO NORDISK A/SInventors: Jesper Lau, Paw Bloch, Jacob Kofoed, Patrick William Garibay
-
Publication number: 20140301974Abstract: The present invention relates to compositions comprising biologically active proteins linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of using such compositions in treatment of glucose-related diseases, metabolic diseases, coagulation disorders, and growth hormone-related disorders and conditions.Type: ApplicationFiled: January 30, 2014Publication date: October 9, 2014Applicant: Amunix Operating Inc.Inventors: Volker Schellenberger, Joshua Silverman, Chia-Wei Wang, Benjamin Spink, Willem P. Stemmer, Nathan Geething, Wayne To, Jeffrey L. Cleland
-
Patent number: 8853159Abstract: The present invention provides fusion peptides having GLP-1 activity and enhanced stability in vivo, in particular resistancy to dipeptidyl peptidase IV. The fusion peptide comprises as component (I) N-terminally a GLP-1(7-35, 7-36 or 7-37) sequence and as component (II) C-terminally a peptide sequence of at least 9 amino acids or a functional fragment, variant or derivative thereof. Component (II) is preferably a full or partial version of IP2 (intervening peptide 2). A preferred embodiment comprises the sequence GLP-1(7-35, 36 or 37)/IP2/GLP-1(7-35, 36 or 37) or GLP-2. The fusion peptide may be produced in engineered cells or synthetically and may be used for preparing a medicament for treating various diseases or disorders, e.g. diabetes type 1 or 2, apoptosis related diseases or neurodegenerative disorders.Type: GrantFiled: May 29, 2012Date of Patent: October 7, 2014Assignee: Biocompatibles UK LtdInventors: Peter Geigle, Christine Wallrapp, Eric Thoenes
-
Patent number: 8853160Abstract: The invention relates to novel polypeptide analogs of GLP-1 and exendin-4. The polypeptide, in a preferred embodiment, is insulinotropic and long-acting. Preferably, the polypeptide's insulinotropic effect is comparable to or exceeds the effect of an equimolar amount of GLP-1 or exendin-4. The invention also relates to a method of treating a subject with diabetes, comprising administering to the subject the polypeptide of the invention in an amount that has an insulinotropic effect. The invention also relates to methods of using GLP-1, exendin-4, and polypeptide analogs thereof for neuroprotective and neurotrophic effects.Type: GrantFiled: August 24, 2012Date of Patent: October 7, 2014Assignee: The United States of America, as represented by the Secretary, Department of Health & Human ServicesInventors: Nigel H. Greig, Josephine M. Egan, Maire Doyle, Harold W. Holloway, Tracy Perry
-
Patent number: RE45313Abstract: The present invention relates to novel peptide conjugates which have increased stability and are useful in the treatment of excess levels of blood glucose.Type: GrantFiled: July 17, 2013Date of Patent: December 30, 2014Assignee: Zealand Pharma A/SInventors: Bjarne Due Larsen, Jens Damsgaard Mikkelsen, Søren Neve